A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance
Samantha L. Grimes(Vanderbilt University Medical Center), Mark R. Denison(Vanderbilt Health), Jordan Anderson-Daniels(Vanderbilt University Medical Center), Jennifer Gribble(Vanderbilt University), Elizabeth A. Campbell(University of Alabama at Birmingham), Xiaotao Lu(Vanderbilt University Medical Center), Gabriel I. Small, Seth A. Darst(Rockefeller University), Young Joo Choi(Rockefeller University), Anoosha Banerjee(Rockefeller University), Alexandra A. Abu-Shmais(Vanderbilt University Medical Center), Maria L. Agostini(VIR Biotechnology (United States)), Andrea J. Pruijssers(Vanderbilt Health)
Cited by 21
Related Papers
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
|Science Translational Medicine|2020|1.2k
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
|Cell Reports|2020|541
Infidelity of SARS-CoV Nsp14-Exonuclease Mutant Virus Replication Is Revealed by Complete Genome Sequencing
|PLoS Pathogens|2010|529
Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design
|Nature Reviews Molecular Cell Biology|2021|522